Choice Of Method Used To Measure Serum Levels Of NfL Should Be Considered When Using It As A Biomarker For ATTR-PN, Research Indicates

Rare Disease Advisor (6/10, Murphy) reports, “The choice of method used to measure serum levels of neurofilament light chain (NfL) should be considered when using it as a biomarker for transthyretin amyloid polyneuropathy (ATTR-PN), according to a study.” Investigators “found that the Ella automated immunoassay reported higher levels of NfL than the Single Molecule Array (SiMoA) immunoassay in 55 symptomatic and presymptomatic patients with hereditary ATTR-PN.” Rare Disease Advisor adds, “The Ella method reported a mean NfL concentration of 27.5 pg/mL in comparison to a mean concentration of 15.9 pg/mL using the SiMoA method,” while “Bland-Altman analysis found a mean bias of 15.4 pg/mL between the 2 methods.” The findings were published in the European Journal of Neurology.